tiprankstipranks
AN2 Therapeutics, Inc. (ANTX)
:ANTX
US Market

AN2 Therapeutics, Inc. (ANTX) AI Stock Analysis

Compare
93 Followers

Top Page

AN

AN2 Therapeutics, Inc.

(NASDAQ:ANTX)

43Neutral
AN2 Therapeutics, Inc. has a challenging financial position typical of early-stage biotech firms, with no revenue and reliance on external funding. While the balance sheet is stable, persistent negative cash flows highlight risks. Technical indicators suggest some positive momentum, but the unfavorable valuation due to lack of profitability limits attractiveness. Overall, the stock is risky with potential for growth if product development succeeds.
Positive Factors
Financial Stability
The company ended the fiscal year with approximately $89 million in cash, providing financial stability through 2027 based on current plans.
Market Opportunity
AN2 Therapeutics anticipates unblinding Phase 3 results for their oral antibiotic candidate, which could lead to a significant market opportunity of over $1 billion.
Regulatory Engagement
AN2 plans to engage with the FDA to explore potential registrational pathways.
Negative Factors
Clinical Challenges
Achieving 3 consecutive months of negative sputum is considered a high bar, especially in patients with severe refractory MAC.
Product Development Setback
AN2 plans to discuss potential registrational pathways in refractory MAC after the Phase 3 data is reported.
Stock Price Performance
The stock price collapsed after disappointing Phase 2 culture conversion data for epetraborole in refractory MAC.

AN2 Therapeutics, Inc. (ANTX) vs. S&P 500 (SPY)

AN2 Therapeutics, Inc. Business Overview & Revenue Model

Company DescriptionAN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
How the Company Makes MoneyAN2 Therapeutics makes money primarily through the development and eventual commercialization of its proprietary drug candidates. The company's revenue model is based on achieving successful clinical trial results that lead to regulatory approvals, which would then allow for the commercialization and sale of its therapeutic products. Key revenue streams include potential product sales, licensing agreements, and partnerships with other pharmaceutical companies. These partnerships may involve collaboration on research and development or co-marketing arrangements that provide upfront payments, milestone payments, and royalties. Additionally, the company may also secure funding through strategic alliances, grants, and investor funding to support its drug development programs.

AN2 Therapeutics, Inc. Financial Statement Overview

Summary
AN2 Therapeutics, Inc. faces typical challenges for a biotech firm at its stage, including lack of revenue and dependence on external funding. While the balance sheet shows a strong equity position and no debt, persistent negative cash flows and losses underscore the need for successful product development or partnerships to achieve financial sustainability.
Income Statement
15
Very Negative
AN2 Therapeutics, Inc. shows no revenue generation, which is typical for early-stage biotech companies. The company has consistently reported negative EBIT and net income, indicating operational and net losses. A lack of revenue growth and continuous losses highlight significant challenges in achieving profitability.
Balance Sheet
40
Negative
The company's financial structure is relatively stable with no debt and positive stockholders' equity, providing a solid equity base. However, the absence of revenue raises concerns about the sustainability of this financial position without additional financing.
Cash Flow
25
Negative
Negative operating and free cash flows are consistent, reflecting cash burn typical for R&D-focused biotech firms. The reliance on financing cash flow indicates dependence on external funding to support operations, which poses a risk if future funding is not secured.
Breakdown
TTMDec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Income StatementTotal Revenue
0.000.000.000.000.000.00
Gross Profit
0.000.00-77.00K0.000.000.00
EBIT
-56.79M-69.64M-42.26M-21.57M-7.28M-5.18M
EBITDA
-36.26M4.90M-42.26M0.00-6.32M0.00
Net Income Common Stockholders
-51.32M-64.73M-41.47M-21.47M-13.60M-5.63M
Balance SheetCash, Cash Equivalents and Short-Term Investments
114.21M107.30M96.06M58.55M4.07M5.60M
Total Assets
121.26M138.74M102.56M65.32M4.23M5.70M
Total Debt
0.000.0053.00K0.000.00728.00K
Net Debt
-24.69M-15.65M-27.17M-12.10M-4.07M-4.87M
Total Liabilities
10.66M14.04M7.19M112.73M24.55M887.00K
Stockholders Equity
110.60M124.70M95.37M-47.41M-20.32M4.81M
Cash FlowFree Cash Flow
-49.26M-53.29M-33.46M-20.48M-5.36M-2.49M
Operating Cash Flow
-49.26M-53.29M-33.46M-20.48M-5.36M-2.49M
Investing Cash Flow
54.59M-43.28M-21.77M-50.02M0.000.00
Financing Cash Flow
372.00K84.99M70.36M78.53M3.84M8.08M

AN2 Therapeutics, Inc. Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1.39
Price Trends
50DMA
1.25
Positive
100DMA
1.28
Positive
200DMA
1.45
Negative
Market Momentum
MACD
0.06
Positive
RSI
50.75
Neutral
STOCH
26.82
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANTX, the sentiment is Negative. The current price of 1.39 is above the 20-day moving average (MA) of 1.39, above the 50-day MA of 1.25, and below the 200-day MA of 1.45, indicating a neutral trend. The MACD of 0.06 indicates Positive momentum. The RSI at 50.75 is Neutral, neither overbought nor oversold. The STOCH value of 26.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ANTX.

AN2 Therapeutics, Inc. Risk Analysis

AN2 Therapeutics, Inc. disclosed 70 risk factors in its most recent earnings report. AN2 Therapeutics, Inc. reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

AN2 Therapeutics, Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
48
Neutral
$6.84B1.02-53.11%2.50%16.84%0.92%
46
Neutral
$41.79M10.83-89.62%-71.68%-397.61%
45
Neutral
$41.22M-139.16%20.58%15.90%
43
Neutral
$40.93M-49.69%38.98%
42
Neutral
$43.42M-102.26%69.37%
34
Underperform
$43.57M607.06%55.67%
28
Underperform
$43.06M<0.01%-29.01%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ANTX
AN2 Therapeutics, Inc.
1.36
-2.40
-63.83%
DYAI
Dyadic International
1.35
-0.32
-19.16%
OTLK
Outlook Therapeutics
1.22
-9.04
-88.11%
SPRO
Spero Therapeutics
0.72
-1.07
-59.78%
XFOR
X4 Pharmaceuticals
0.24
-1.17
-82.98%
ITRM
Iterum Therapeutics
1.23
-0.41
-25.00%

AN2 Therapeutics, Inc. Corporate Events

Executive/Board ChangesBusiness Operations and Strategy
AN2 Therapeutics Promotes Joshua Eizen to Key Roles
Positive
Nov 5, 2024

AN2 Therapeutics has promoted its Chief Legal Counsel, Joshua Eizen, to the roles of Chief Legal Officer and Chief Operating Officer, effective immediately. Eizen’s new compensation package includes a salary of $450,000, stock options, and restricted stock units that vest over time. This move is part of AN2’s strategic efforts to strengthen its leadership team, appealing to investors looking at executive management changes.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.